Genprex Inc(GNPX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 29 at 5:29 AM ET (Korea 9/29 18:29)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -158.75 | Insider Own | 0.21% | Shs Outstand | 0.8M | Perf Week | -19.25% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | -1.03% | Shs Float | 0.8M | Perf Month | -22.16% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | - | Inst Own | 1.66% | Short Float | 10.09% | Perf Quarter | -74.71% |
| Income | -0.02B | P/S | - | EPS this Y | - | Inst Trans | 1.22% | Short Ratio | 0.38 | Perf Half Y | -92.98% |
| Sales | 0.00B | P/B | 0.1 | EPS next 5Y | - | ROA | -157.4% | Short Interest | 0.08M | Perf YTD | -92.7% |
| Book/sh | 29.23 | P/C | 0.15 | EPS past 3/5Y | 74% 55.62% | ROE | -203.86% | 52W High | -99.77% ($1210.00) | Perf Year | -98.57% |
| Cash/sh | 18.46 | P/FCF | - | Sales past 3/5Y | - | ROIC | -111.51% | 52W Low | -13.8% ($3.26) | Perf 3Y | -99.98% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 93.08% | Gross Margin | - | Volatility(W/M) | 14.13% 7.46% | Perf 5Y | -100% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.37 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 6.77 | EPS Q/Q | 94.96% | Profit Margin | - | RSI (14) | 27.14 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.77 | Sales Q/Q | - | SMA20 | -18.36% ($3.44) | Beta | -0.99 | Target Price | $8250 |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -38.15% ($4.54) | Rel Volume | 2.59 | Prev Close | $3.29 |
| Employees | 13 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -89.2% ($26.02) | Avg Volume(3M) | 0.22M | Price | $2.81 |
| IPO | 2018/3/29 | Option/Short | No/Yes | Trades | 2612 | Volume | 568,365 | Change | -14.59% |
🧬 Genprex () is a US clinical-stage biotech developing gene therapies for cancer and diabetes treatment. Its lead candidate, Reqorsa® (quaratusugene ozeplasmid), is a non-viral gene therapy based on the TUSC2 tumor suppressor gene, with ongoing lung cancer clinical trials (Acclaim-1 and Acclaim-3) in combination with the EGFR-targeted therapy Tagrisso and the immunotherapy Tecentriq.
Over the past 1 year, on the lower side
100% below its 1-year high.
Traded more than usual That is 259% of its average volume.
GNPX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +77% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 1.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #583 of 592 in the industry
Based on market cap of $2M.
FAQ
What kind of company is GNPX?
GNPX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of GNPX?
The market cap of GNPX is approximately $2M, ranking 5,836 within its sector.
What is the 52-week high and low for GNPX?
GNPX has recorded a 52-week high of $1210.00 and a low of $3.26.
